Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > ULURU Inc. to List Shares on American Stock Exchange Under Stock Symbol 'ULU'

Abstract:
ULURU Inc. (BULLETIN BOARD: ULUR) , today announced its shares have been accepted for listing on the American Stock Exchange (Amex(R)) under the symbol "ULU".

ULURU Inc. to List Shares on American Stock Exchange Under Stock Symbol 'ULU'

ADDISON, TX | Posted on July 25th, 2007

"ULURU is moving to the Amex(R) because it reinforces our strategic initiative to maximize shareholder value," said Kerry P. Gray, ULURU's President and Chief Executive Officer. "Listing on the Amex(R) brings more stability to the trading environment and process, and should help increase ULURU's exposure to the investment community. Additionally, trading on the Amex(R) will make it easier for retail stockbrokers to participate in the market for our common stock."

John McGonegal, senior vice president of the Amex Equities Group, said: "We are excited to welcome ULURU Inc., to the American Stock Exchange. We look forward to providing them the support and services a growing company needs to compete in today's marketplace."

ULURU shares are expected to begin trading on Amex(R) on July 26, 2007. The Amex's approval is contingent upon ULURU being in compliance with all applicable listing standards on the date its stock begins trading on the Amex(R) and may be rescinded if ULURU is not in compliance with such standards. ULURU was previously traded on the OTCBB.

####

About ULURU Inc.
ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com/.

About American Stock Exchange:

The American Stock Exchange(R) (Amex(R)) is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex(R) is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex(R) lists 164 ETFs to date. The Amex(R) is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating) relating to our expected listing on Amex(R). When used in this press release, the words "may," "targets," "goal," "could," "should," "would," "believe," "feel," "expects," "confident," "anticipate," "estimate," "intend," "plan," "potential" and similar expressions may be indicative of forward-looking statements including without limitation statements relating to the progress of our technology with corporate partners favorably impacting 2007 performance, pre-clinical results for our products and advantages of our products. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. The Company cautions that various factors, including the factors described hereunder and those discussed in the Company's other filings with the Securities and Exchange Commission, as well as general economic conditions, industry trends, collect accounts receivable, hire and retain qualified personnel, Food and Drug Administration regulations, adverse litigation, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements of the Company made by or on behalf of the Company. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of an unanticipated event. New factors emerge from time to time, and it is not possible for management to predict all of such factors. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 and other reports filed by us with the Securities and Exchange Commission.

For more information, please click here

Contacts:
Company Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145
ULURU Inc.

CONTACT: Kerry P. Gray
President & CEO
or
Terry K. Wallberg
Vice President & CFO
+1-214-905-5145
both of ULURU Inc.

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Nanomedicine

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project